17 news items
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
ANNX
17 Jun 24
. Annexon's novel scientific approach targets upstream C1q to block the classical complement inflammatory cascade before it starts, and its therapeutic
Annexon Announces Pricing of $125 Million Underwritten Public Offering
ANNX
5 Jun 24
approach targets upstream C1q to block the classical complement inflammatory cascade before it starts, and its therapeutic candidates are designed to provide
Annexon Announces Proposed Public Offering of Common Stock
ANNX
4 Jun 24
. Annexon's novel scientific approach targets upstream C1q to block the classical complement inflammatory cascade before it starts, and its therapeutic
Needham Reiterates Buy on Annexon, Maintains $16 Price Target
ANNX
4 Jun 24
Needham analyst Joseph Stringer reiterates Annexon (NASDAQ:ANNX) with a Buy and maintains $16 price target.
HC Wainwright & Co. Reiterates Buy on Annexon, Maintains $30 Price Target
ANNX
4 Jun 24
HC Wainwright & Co. analyst Andrew Fein reiterates Annexon (NASDAQ:ANNX) with a Buy and maintains $30 price target.
zt5ab96l 8eqwlxjf9ocxxjt9
AGEN
ANNX
BOOT
4 Jun 24
Clinch upgraded Upstart from Sell to Neutral and raised the price target from $22.5 to $25.5.
Now Read This: Best Buy, McKesson And 2 Other Stocks Insiders Are Selling
li7tbhs6x hgv6y0lc
ANNX
3 Jun 24
diseases of the body, brain, and eye. Annexon's novel scientific approach targets upstream C1q to block the classical complement inflammatory cascade
zbhgs314s1vit4wrdc267bph704m5h0s1jt9lq
ANNX
16 May 24
novel scientific approach targets upstream C1q to block the classical complement inflammatory cascade before it starts, and its therapeutic
v54n7 xlyhjvhslp3357ohk07xpmmuzyfc0
ANNX
15 May 24
Wells Fargo analyst Derek Archila maintains Annexon (NASDAQ:ANNX) with a Overweight and lowers the price target from $12 to $10.
1q3hvacle6akdaoistdkkr98y6f4bxjzl5tv79asf4efo9az839g
ANNX
14 May 24
HC Wainwright & Co. analyst Andrew Fein reiterates Annexon (NASDAQ:ANNX) with a Buy and maintains $30 price target.
feq5yd8u83et
ANNX
13 May 24
Needham analyst Joseph Stringer reiterates Annexon (NASDAQ:ANNX) with a Buy and maintains $16 price target.
dn5 fo7scut76u
ANNX
7 May 24
-mediated neuroinflammatory diseases of the body, brain, and eye. Annexon's novel scientific approach targets upstream C1q to block the classical
m36z5509xle1dei4vli01nsbpzqc5ci4hh4kqldfvicdin04x0axq
ANNX
1 May 24
diseases of the body, brain, and eye. Annexon's novel scientific approach targets upstream C1q to block the classical complement inflammatory cascade before
go3cg7 zw4pktfeilqnoz1fqiurx3yn7o6ju5rjwn057d5si
ANNX
16 Apr 24
novel scientific approach targets upstream C1q to block the classical complement inflammatory cascade before it starts, and its therapeutic candidates
wd97uike5yznwfbv509u c2xm
ANNX
11 Apr 24
Needham analyst Joseph Stringer reiterates Annexon (NASDAQ:ANNX) with a Buy and maintains $16 price target.
kb1shmelfcfsn56xgaagp5hhqhee5ixr1d4cvlzx27
ANNX
1 Apr 24
Wells Fargo analyst Derek Archila maintains Annexon (NASDAQ:ANNX) with a Overweight and maintains $12 price target.
oc6cw2cifgdk57w7
ANNX
1 Apr 24
JP Morgan analyst Anupam Rama maintains Annexon (NASDAQ:ANNX) with a Overweight and raises the price target from $11 to $13.
- Prev
- 1
- Next